Featured Attorney

Neil S. Bromberg

Partner

Mr. Bromberg specializes in pharmaceutical product liability and toxic tort defense and has broad state and federal litigation expertise.  He has extensive experience representing gasoline manufacturers in personal injury and wrongful death litigation involving alleged exposure to benzene.  In 2011, Mr. Bromberg was co-lead counsel in a major defense verdict in the first New Jersey drug product bellwether trial involving the oncology drug Zometa®. Read more >

Opinions

• Harvey v. Novartis Pharms. Corp., No. 2:06-CV-1140-VEH (N.D. Ala. Jan. 12, 2012)

  Plaintiff's untimely effort to designate retained expert witness on specific causation rejected by the Northern District of Alabama in Aredia®/Zometa® case.

• McDaniel v. Novartis Pharmaceuticals Corporation, No. 2:08-cv-02088-PKH (W.D. Ark. Jan. 6, 2012)

  U.S. District Court for the Western District of Arkansas dismisses Aredia® case on the eve of trial, granting judgment in favor of Novartis Pharmaceuticals Corporation. 

• Brown v. Novartis Pharm. Corp., No. 7:08-CV-00130-FL (E.D.N.C. Dec. 16, 2011)

  North Carolina Federal Magistrate says New Jersey law should govern punitive damages in Aredia®/Zometa® case.
  

• Eberhart v. Novartis Pharmaceuticals Corporation, No. 1:08-cv-2542-WSD, slip op. (October 31, 2011, N.D. Ga.)

  U. S. District Court for the Northern District of Georgia grants summary judgment in favor of Firm client Novartis Pharmaceuticals Corporation in a case concerning plaintiff's treatment with Novartis's drugs Aredia® and Zometa®.

• McPhee v. General Elec. Int’l, Inc., 426 Fed. App’x 33 (2d Cir. 2011)

  Second Circuit upholds contractual choice-of-law provision and affirms summary judgment in favor of Firm client General Electric International, Inc.

Search Hollingsworth LLP's opinions from across the country. >